# Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia

> **NCT00401089** · PHASE1,PHASE2 · COMPLETED · sponsor: **London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's** · enrollment: 60 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder
- Tardive Dyskinesia
- Insulin Resistance
- Obesity

## Interventions

- **DRUG:** Panax Ginseng

## Key facts

- **NCT ID:** NCT00401089
- **Lead sponsor:** London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2006-12
- **Final completion:** 2007-10
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2012-12-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00401089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00401089, "Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00401089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*